Testing selatogrel to prevent problems after a recent heart attack
Part of Cancer clinical trials.
This trial tests selatogrel to see if it can better prevent harmful heart and blood-clot outcomes after a recent heart attack. You may be considered if you had a heart attack in the past 4 weeks and have higher-risk heart artery disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a type 1 heart attack (STEMI or NSTEMI) with symptoms within the last 4 weeks
- You have multivessel blocked heart arteries (significant narrowing in 2+ artery areas) plus at least one added risk factor
- You had successful training to use the at-home injector and can correctly self-administer the placebo
- You do NOT have a high bleeding risk, including prior brain bleeding or certain recent stomach bleeding
- Your blood counts and organs are in a safe range (not very low blood hemoglobin or platelets, and no major severe liver problem)
- You have not had certain stroke types recently and are not on specific strong blood-thinning combinations
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether starting an SGLT-2 inhibitor around the time of a heart attack can reduce heart damage size and improve how the heart heals. It focuses on people with a high risk of developing heart failure and who are getting a procedure to open blocked heart arteries.
This study tests a new medication called selatogrel in people with chronic coronary syndrome (long-term heart disease caused by narrowed heart arteries). Researchers want to see how the body processes this drug and whether it helps prevent future heart problems.
This trial tests whether taking ticagrelor (a blood thinner) alone, without aspirin, is safe and effective for people who have had a heart attack and are being treated with medication only (no stents or bypass surgery). It could mean fewer pills and possibly reduce bleeding risks.
This study tests an investigational drug called SGC001 for people having a heart attack affecting the front wall of the heart. The goal is to see if adding this drug to the standard artery-opening procedure helps improve outcomes.
This trial tests whether a low-dose clot-busting medicine placed into the heart artery after a primary stent can improve outcomes in people with a certain type of heart attack. It also involves short hospital follow-ups and a heart MRI to look at how the heart is recovering.
This trial tests a new drug given shortly after a first heart attack to see if it can reduce heart damage when blood flow is restored. It is for patients having a specific type of heart attack (STEMI) and getting a procedure to open the blocked artery within 6 hours of symptoms starting.
Hear when a new Acute Myocardial Infarction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.